Boundless Bio Stock Quote BOLD - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

4.08

Bid

3.58

Ask

4.63

Volume

39,760

3.94 Day's Range 4.29

3.75 52 Week Range 15.20

Market Cap

93.469M

Previous Close

4.20

Open

4.29

Last Trade

461

4.08

(priorref)

Last Trade Time

Financial Volume

$ 162,634

VWAP

4.0904

Average Volume (3m)

108,354

Shares Outstanding

22,254,537

Dividend Yield

PE Ratio

-1.84

Earnings Per Share (EPS)

-2.22

Revenue

Net Profit

-49.43M

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.boundlessbio.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Boundless Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BOLD. The last closing price for Boundless Bio was $4.20. Over the last year, Boundless Bio shares have traded in a share price range of $ 3.75 to $ 15.20.

Boundless Bio currently has 22,254,537 shares outstanding. The market capitalization of Boundless Bio is $93.47 million. Boundless Bio has a price to earnings ratio (PE ratio) of -1.84.

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2...

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer...

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.16	-3.77358490566	4.24	4.5284	3.94	48039	4.27418339	CS
4	-3.18	-43.8016528926	7.26	7.57	3.75	140402	5.14269798	CS
12	-7.42	-64.5217391304	11.5	12.6484	3.75	108354	8.11406636	CS
26	-10.17	-71.3684210526	14.25	15.2	3.75	142410	10.03412985	CS
52	-10.17	-71.3684210526	14.25	15.2	3.75	142410	10.03412985	CS
156	-10.17	-71.3684210526	14.25	15.2	3.75	142410	10.03412985	CS
260	-30.09	-88.0597014925	34.17	60	3.75	584958	45.94727817	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VEVVicinity Motor Corporation	$ 0.7131 (122.15%)	116.26M
QLGNQualigen Therapeutics Inc	$ 0.428851 (108.89%)	420.2M
IVPInspire Veterinary Partners Inc	$ 10.52 (88.19%)	41.79M
TOYOTOYO Company Ltd	$ 2.699 (74.13%)	56.65M
NISNNiSun International Enterprise Development Group Company Ltd	$ 9.11 (51.33%)	7.4M
SISIShineco Inc	$ 0.8446 (-60.16%)	6.71M
MCACMonterey Capital Acquisition Corporation	$ 3.54 (-49.50%)	364.7k
MCACUMonterey Capital Acquisition Corporation	$ 7.64 (-28.40%)	2.61k
GENEGenetic Technologies Ltd	$ 0.80 (-27.93%)	780.46k
KZIAKazia Therapeutics Ltd	$ 0.8975 (-27.62%)	25.62M
QLGNQualigen Therapeutics Inc	$ 0.428851 (108.89%)	420.2M
MAXNMaxeon Solar Technologies Ltd	$ 0.237 (-1.54%)	286.13M
NVDANVIDIA Corporation	$ 129.24 (1.44%)	251.65M
AGRIAgriFORCE Growing Systems Ltd	$ 0.1001 (21.92%)	192.82M
LCIDLucid Group Inc	$ 4.25 (25.00%)	167.79M